TrkC receptor antagonists - Pipeline Insight, 2025

DelveInsight’s, “TrkC receptor antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in TrkC receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TrkC receptor antagonists Understanding

TrkC receptor antagonists: Overview

Trk receptors are a family of tyrosine kinases that regulates synaptic strength and plasticity in the mammalian nervous system. Trk receptors affect neuronal survival and differentiation through several signaling cascades. However, the activation of these receptors also has significant effects on functional properties of neurons. TrkC is ordinarily activated by binding with NT-3 and has little activation by other ligands. (TrkA and TrkB also bind NT-3, but to a lesser extent).TrkC is mostly expressed by proprioceptive sensory neurons. The axons of these proprioceptive sensory neurons are much thicker than those of nociceptive sensory neurons, which express trkA.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence TrkC receptor antagonists R&D. The therapies under development are focused on novel approaches for TrkC receptor antagonists.

TrkC receptor antagonists Emerging Drugs Chapters

This segment of the TrkC receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TrkC receptor antagonists Emerging Drugs

• Ensartinib: Betta Pharmaceuticals

Ensartinib hydrochloride is a potent and highly selective next-generation ALK inhibitor with independent intellectual property rights, and it is developed jointly by Betta Pharmaceuticals Co., Ltd. and its subsidiary Xcovey Holding, Inc. (Xcovery). Ensartinib hydrochloride is another product following the EGFR-TKI in Betta’s lung cancer pipeline, and it is expected to be the first innovative targeted drug for lung cancer which is launched globally by a Chinese company. Ensartinib (X-396) is a novel II generation, aminopyridazine-based ALK-TKI able to inhibit both wild-type ALK and all evaluated ALK variants (F1174, C1156Y, L1196M, S1206R, T1151, and G1202R mutants) with in vitro IC50 of <4 nM; it also potently inhibits TPM3-TRKA, TRKC, ROS1, EphA2, EphA1, EphB1 and c-MET. Preclinical data demonstrated increased potency of the drug as compared with crizotinib and other II generation TKIs.

• Repotrectinib: Turning Point Therapeutics

Repotrectinib is a small (low molecular weight), macrocyclic tyrosine kinase inhibitor of ROS1, TRK and ALK. Repotrectinib was designed to efficiently bind with the active kinase conformation and avoid steric interference from a variety of clinically resistant mutations. The compact and rigid structure is believed to enable repotrectinib to precisely and efficiently bind deep into the ATP binding pocket of the kinase, and potentially circumvent the steric interference that results in resistance to bulkier kinase inhibitors, especially the solvent-front and gatekeeper mutations of ROS1, TRK and ALK kinases.

Further product details are provided in the report……..

TrkC receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different TrkC receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on TrkC receptor antagonists

There are approx. 7+ key companies which are developing the TrkC receptor antagonists. The companies which have their TrkC receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Turning Point Therapeutics.

• Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

TrkC receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TrkC receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TrkC receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TrkC receptor antagonists drugs.

TrkC receptor antagonists Report Insights

• TrkC receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TrkC receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing TrkC receptor antagonists drugs?
• How many TrkC receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TrkC receptor antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TrkC receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TrkC receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Betta Pharmaceuticals
• Turning Point Therapeutics
• AnHeart Therapeutics
• Roche
• Pyramid Biosciences
• Chia Tai Tianqing Pharmaceutical Group
• Jiangsu Carephar Pharmaceutical
• Bayer
• Plexxikon

Key Products

• Ensartinib
• Repotrectinib
• Taletrectinib
• Entrectinib
• PBI 200
• TQB 3558
• KFP H013
• Larotrectinib
• PLX 7486

Show more